Gene Therapy Pioneer Targets Genetic Disorders with Innovative Delivery System
Abeona Therapeutics Inc. (NASDAQ:ABEO) is at the forefront of developing groundbreaking gene and cell therapies for severe genetic disorders. The company’s proprietary AIM platform leverages adeno-associated virus (AAV) vectors to precisely deliver genetic material, restoring functionality across multiple organs in the body.
Note: The author has no financial interest or affiliation with any companies mentioned and is not receiving compensation for this article. Opinions expressed are those of the author and do not reflect the views of Seeking Alpha or any other entity.
Leave a Reply